Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Grows By 176.3%

Kalaris Therapeutics Inc. (NASDAQ:KLRS) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totaling 516,700 shares, a growth of 176.3% from the August 31st total of 187,000 shares. Based on an average trading volume of 269,500 shares, the days-to-cover ratio is currently 1.9 days. Approximately 10.0% of the company’s stock are short sold. Approximately 10.0% of the company’s stock are short sold. Based on an average trading volume of 269,500 shares, the days-to-cover ratio is currently 1.9 days.

Kalaris Therapeutics Stock Performance

KLRS stock opened at $6.64 on Friday. Kalaris Therapeutics has a twelve month low of $2.14 and a twelve month high of $24.15. The company’s 50-day moving average is $3.79.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.10).

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on KLRS shares. Wall Street Zen raised Kalaris Therapeutics to a “hold” rating in a research report on Friday. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Kalaris Therapeutics in a research report on Saturday, September 27th. Piper Sandler set a $3.00 price objective on Kalaris Therapeutics and gave the company a “neutral” rating in a research report on Wednesday, July 23rd. Finally, Raymond James Financial started coverage on Kalaris Therapeutics in a research report on Tuesday, September 2nd. They set a “strong-buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $3.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Kalaris Therapeutics stock. XTX Topco Ltd bought a new stake in shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 24,234 shares of the company’s stock, valued at approximately $65,000. XTX Topco Ltd owned 0.13% of Kalaris Therapeutics at the end of the most recent quarter. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.